All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The virtual Lymphoma Hub Satellite Symposium, at the 16th International Conference on Malignant Lymphoma (16-ICML), saw a panel of international experts come together to discuss the sequencing of therapies in high-risk relapsed/refractory lymphoma and chronic lymphocytic leukemia (CLL). Professor Francesc Bosch, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES, discusses treatment options for a patient with ibrutinib-resistant CLL.
Treatment options for a patient with ibrutinib-resistant CLL
Bosch presents his treatment approach to a double-refractory ibrutinib-resistant patient case by firstly discussing the significance of predictive markers and how to use these to discern between different treatments. He then moves on to outline the therapeutic options for this case, including alternative BTK inhibitors, PI3 kinase inhibitors, and CAR T-cell therapy.
Satellite Symposium | Treatment options for a patient with ibrutinib-resistant CLL
If you would like to download the slides from Francesc Bosch's presentation, click below
Download hereUnderstanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox